As of September 30, 2026, Rallybio Corporation carries a market capitalization of 91.73M, placing it among publicly traded companies globally. Its enterprise value stands at 1.04M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 91.73M |
| Enterprise Value | 1.04M |
Rallybio Corporation's next confirmed earnings release is scheduled for March 11, 2027.
| Earnings Date | 3/11/2027 |
As of September 30, 2026, Rallybio Corporation has 5.33M shares outstanding.
| Shares Outstanding | 5.33M |
As of September 30, 2026, Rallybio Corporation trades at a trailing price-to-earnings ratio of 3.59. The price-to-sales ratio is 221.80, and the price-to-book ratio stands at 0.99.
| PE Ratio | 3.59 |
| PS Ratio | 221.80 |
| PB Ratio | 0.99 |
| P/TBV Ratio | 0.99 |
| P/FCF Ratio | 3.12 |
| P/OCF Ratio | 3.11 |
These figures are as of September 30, 2026. The EV/Sales ratio of 2.39 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Rallybio Corporation trades at an EV/FCF ratio of 0.03, comparing the total takeover cost of the business to the cash it actually generates for all capital providers. These enterprise value multiples are built on an enterprise value of 1.04M versus a market cap of 91.73M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 2.39 |
| EV / FCF | 0.03 |
As of September 30, 2026, Rallybio Corporation maintains a current ratio of 28.87, meaning it holds 28.9x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 28.87 |
| Quick Ratio | 27.63 |
Over the twelve months ended September 30, 2026, Rallybio Corporation posted a return on equity (ROE) of 34.52, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -29.34, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 32.85, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 34.48, useful for judging operating efficiency across full business cycles. The company generates approximately 31,000.00 in revenue per employee across its workforce of 14.00, a quick read on workforce productivity versus industry peers.
| Return on Equity (ROE) | 34.52 |
| Return on Assets (ROA) | 32.85 |
| Return on Invested Capital (ROIC) | -29.34 |
| Return on Capital Employed (ROCE) | 34.48 |
| Revenue Per Employee | 31,000.00 |
| Employee Count | 14.00 |
Over the twelve months ended September 30, 2026, Rallybio Corporation recorded 1.40M in income tax expense. That works out to an effective tax rate of 4.98, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 28.21M, leaving 26.81M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | 1.40M |
| Effective Tax Rate | 4.98 |
As of the close on November 16, 2026, Rallybio Corporation's stock has gained approximately 201.18% over the past 52 weeks. The 50-day moving average sits at 16.49, while the 200-day moving average is 13.51.
| 52-Week Price Change | 201.18% |
| 50-Day Moving Average | 16.49 |
| 200-Day Moving Average | 13.51 |
Over the twelve months ended September 30, 2026, Rallybio Corporation generated 434,000.00 in revenue and converted that into 26.81M in net income, yielding earnings per share of 4.77. EBITDA reached -24.21M, while operating income came in at -24.22M.
| Revenue | 434,000.00 |
| Operating Income | -24.22M |
| Pretax Income | 28.21M |
| Net Income | 26.81M |
| EBITDA | -24.21M |
| EBIT | -24.22M |
| Earnings Per Share (EPS) | 4.77 |
As of September 30, 2026, Rallybio Corporation holds 90.69M in cash and equivalents against - - in total debt, resulting in a net debt position of -90.69M. Total book value stands at 92.30M, with working capital of 91.49M providing operational flexibility.
| Cash & Cash Equivalents | 90.69M |
| Net Debt | -90.69M |
| Equity (Book Value) | 92.30M |
| Book Value Per Share | 17.31 |
| Working Capital | 91.49M |
Rallybio Corporation produced 30.99M in operating cash flow over the twelve months ended September 30, 2026.
| Operating Cash Flow | 30.99M |
| Free Cash Flow | 30.99M |
| FCF Per Share | 5.54 |
These figures cover the twelve months ended September 30, 2026. The operating margin of -5,580.88 and net profit margin of 6,177.42 provide insight into operational efficiency.
| Operating Margin | -5,580.88 |
| Pretax Margin | 6,500.92 |
| Profit Margin | 6,177.42 |
| EBITDA Margin | -5,579.03 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 32.05, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -0.28, meaning Rallybio Corporation raised more capital through share issuance and new debt than it returned via dividends and buybacks.
| Shareholder Yield | -0.28 |
| FCF Yield | 32.05 |
Rallybio Corporation's most recent stock split took place on February 6, 2026 with a 8:1 split ratio.
| Last Split Date | 2/6/2026 |
| Split Ratio | 8:1 |
As of September 30, 2026, Rallybio Corporation has an Altman Z-Score of 13.14, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 13.14 |